Investigating how a specific protein affects immune responses in cancer patients
Wnt3a is a central regulator for P. gingivalis-mediated expression of PD-L1 and suppression of CD8+ T cell activity
This study is looking at how a specific bacterium affects the immune system's ability to fight cancer by changing the levels of a protein called PD-L1 on certain immune cells, which could help improve cancer treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10693322 on NIH RePORTER |
What this research studies
This research explores the role of Wnt3a in regulating PD-L1 expression on dendritic cells, which is crucial for the effectiveness of immunotherapy in cancer treatment. It focuses on understanding how the bacterium Porphyromonas gingivalis influences PD-L1 levels and CD8+ T cell activity, which are vital for the immune system's ability to fight cancer. By identifying the mechanisms behind these interactions, the study aims to uncover new therapeutic targets that could enhance immune responses in patients. The approach involves analyzing immune cell behavior in response to bacterial infection and its implications for cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who may have chronic infections or are experiencing immune system challenges.
Not a fit: Patients without cancer or chronic infections may not benefit from the findings of this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for cancer patients, enhancing their immune response against tumors.
How similar studies have performed: Previous research has shown promising results in understanding immune modulation through similar pathways, indicating potential for success in this area.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Wang, Huizhi — Virginia Commonwealth University
- Study coordinator: Wang, Huizhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.